Singapore-based TauRx will update on Phase III studies of its tau aggregation inhibitor LMTX in a podium presentation at the Alzheimer’s Association…

Shortages of vaccines at clinics in China have predictably followed a move to eliminate middlemen from the sales chain.

China Resources has teamed up with Australian investment bank Macquarie to buy a majority of cancer and cardio medical care provider GenesisCare in a $1.3…

China’s Jilin Zixin Pharmaceutical Industrial has splashed out $42 million to buy a Rhode Island-based high-definition genome mapping company, Nabsys 2.0.

Biocon said in its first-quarter earnings that biosimilar applications for Humira and Herceptin are due to be filed in the U.S. and EU in the company's…

Abbott Laboratories CEO Miles White noted weaker pediatric nutrition sales--milk powder--in China in the second quarter.

A Chinese research team from Sichuan University is set for the first in vivo CRISPR trial.

Osaka-based Takeda Pharmaceutical is reviewing prospects to sell a majority stake in Wako Pure Chemical.

Mylan and Biocon said the European Medicines Agency has accepted an application for review for marketing authorization of a biosimilar of pegfilgrastim.